Carlsbad, CA, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that the Company’s special meeting of stockholders held on September 18, 2025 at 9:00 a.m. Pacific Time was convened and adjourned, without any business being conducted, due to lack of the required quorum. A quorum cons ...